SEC Form 4 · accession 0001493152-26-030207
Akari Therapeutics Plc · AKTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Abizer Gaslightwala
Officer — CEO · Director
Period of report
Jun 24, 2026
Accepted (ET)
Jun 25, 2026 · 8:04 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001541157
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.64 | Jun 24, 2026 | A | 5,500 | A | Jun 24, 2026 | Apr 1, 2036 | American Depositary Shares representing Ordinary Shares | 5,500 | 5,500 | D |
| Stock Option (Right to Buy) | $14.63 | Jun 24, 2026 | A | 15,563 | A | Jun 24, 2026 | Jun 24, 2036 | American Depositary Shares representing Ordinary Shares | 15,563 | 15,563 | D |
Explanation of responses
- F1On April 1, 2026, the reporting person was granted an option to purchase 15,000 American Depositary Shares, with each American Depositary Share representing 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The option vests in three installments based on the closing of qualified financings of at least $15,000,000 in gross proceeds on or before June 30, 2026. The Issuer closed a qualified financing of $5,500,000, resulting in the vesting of the option as to 5,500 American Depositary Shares.